Arshoff Larry, Hoag Gordon, Ivany Craig, Kinniburgh David
Diagnosis, Solutions & Results Inc., Thornhill, Ontario, Canada.
Medical Biochemistry Division, 8204Vancouver Island Health Authority, Victoria, British Columbia, Canada.
Healthc Manage Forum. 2021 May;34(3):175-180. doi: 10.1177/0840470421990041. Epub 2021 Feb 23.
Value-Based Healthcare (VBHC) aims to improve the overall quality, safety, and sustainability of healthcare while reducing delivery costs of more effective care. Despite advantages associated with VBHC transformation, the road to its adoption has been lengthy. Laboratory Medicine (LM) is in a prime position to lead the transition to VBHC because of its key role in diagnosis and treatment of patients. Laboratory medicine results inform/influence 50% to 70% of all clinical decisions. This article summarizes some issues associated with adoption of VBHC and related healthcare innovations and suggests potential approaches using LM-specific examples to help accelerate adoption. Laboratory medicine is both a useful model for VBHC implementation and facilitator for related innovation adoption by helping to target patient populations that would benefit most from specific interventions. The critical value of rapidly adopted diagnostic technologies used during the COVID-19 pandemic and economic recovery provide important insights about the need to embrace and accelerate VBHC implementation.
基于价值的医疗保健(VBHC)旨在提高医疗保健的整体质量、安全性和可持续性,同时降低更有效护理的交付成本。尽管VBHC转型具有诸多优势,但其采用之路却漫长。检验医学(LM)因其在患者诊断和治疗中的关键作用,处于引领向VBHC转型的有利地位。检验医学结果为所有临床决策提供依据/产生影响的比例达50%至70%。本文总结了与采用VBHC及相关医疗保健创新相关的一些问题,并通过检验医学的具体示例提出了潜在方法,以帮助加速采用。检验医学既是VBHC实施的有用模式,也是相关创新采用的促进因素,有助于确定能从特定干预措施中获益最大的患者群体。在新冠疫情期间和经济复苏过程中迅速采用的诊断技术的关键价值,为接受并加速VBHC实施的必要性提供了重要见解。